Given its important prognostic role in cancers, plasma fibrinogen may be combined with other conventional tumor biomarkers such as CEA and carbohydrate antigen 19–9 (CA19–9), which could improve its diagnostic specificity and prognostic assessment in GC. The gene discussed is CEACAM5; the disease is neoplasm.